BioGlue in 2011: what is its role in cardiac surgery?
BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effective use.
Department of Surgery, State University of New York Upstate Medical University, Syracuse, New York, USA.
Castigliano M
CM
Bhamidipati
Joseph S
JS
Coselli
Scott A
SA
LeMaire
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D013504:Cardiovascular Surgical Procedures / Q000009:adverse effects*; D006470:Hemorrhage / Q000209:etiology* / Q000517:prevention & control*; D006488:Hemostasis, Surgical; D006801:Humans; D011506:Proteins / Q000009:adverse effects / Q000627:therapeutic use*
C472676:Bio-glue; D011506:Proteins